Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 5.36 -0.06 (-1.11%) Market Cap: 766.58 Mil Enterprise Value: 543.79 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 72/100

Q2 2019 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Aug 06, 2019 / 08:30PM GMT
Release Date Price: $6.02 (-1.31%)
Operator

Greetings, and welcome to Aurinia Pharmaceuticals Inc. Second Quarter 2019 Conference Call. (Operator Instructions). Please note, this conference is being recorded.

I would now like to introduce you to today's host, Dr. Glenn Schulman. Thank you. You may begin.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thanks, Kevin, and good afternoon, everyone. Welcome to Aurinia's Second Quarter 2019 Results Conference Call. Joining me on today's call from the Aurinia team are Mr. Peter Greenleaf, President and CEO; Dennis Bourgeault, our CFO; Dr. Neil Solomons, Chief Medical Officer; Michael Martin, Chief Operating Officer of Aurinia; and Dr. Simrat, our Head of Medical Affairs. This afternoon, we issued our press release detailing our second quarter 2019 financial results. The press release and associated financial statement package is available on our website at www.auriniapharma.com and a 6-K was filed as well with the SEC.

I'd like to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot